---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-238237"
form_type: "8-K"
ticker: "TCRT"
cik: "0001107421"
company_name: "Alaunos Therapeutics, Inc."
filed_at: "2026-05-26T15:00:21+00:00"
generated_at: "2026-05-26T15:02:37.902818+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Alaunos reports ALN1003 preclinical data: -12.9% weight loss, liver weight -43%; cash only $0.35M

## Summary
- ALN1003 in DIO mice: mean body weight change -12.9% by Day 33 and -10.3% by Day 48 (p<0.0001).
- Liver weight reduced 43% (p<0.0001); lower ALT, AST, ALP and improved histology in treated animals.
- Favorable body composition shift: fat -44.6% (grams), lean +17.2% as % body weight (high dose).
- Cash and cash equivalents $0.354M as of March 31, 2026; runway into Q2 2026, needs additional financing.
- Data from non-GLP mouse studies only; ALN1003 has not been tested in humans.

## SEC filing metadata
- accession: 0001193125-26-238237
- form_type: 8-K
- ticker: TCRT
- cik: 0001107421
- company_name: Alaunos Therapeutics, Inc.
- filed_at: 2026-05-26T15:00:21+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.65
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1107421/000119312526238237/0001193125-26-238237-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1107421/000119312526238237/tcrt-20260526.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-238237
- JSON: https://secwatch.observer/filing/0001193125-26-238237.json
- Plain text: https://secwatch.observer/filing/0001193125-26-238237.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.